Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Opal

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
JAMA|February 24, 2016
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)Mervyn Singer, Clifford S Deutschman, Christopher Warren Seymour, et al.
JAMA|May 20, 2019
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisChristopher W Seymour, Jason N Kennedy, Shu Wang, et al.
JAMA|May 20, 2019
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical TrialJean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, et al.
Critical Care Medicine|January 29, 2013
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012R Phillip Dellinger, Mitchell M Levy, Andrew Rhodes, et al.
Intensive Care Medicine|January 31, 2013
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012R P Dellinger, Mitchell M Levy, Andrew Rhodes, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
JAMA|October 3, 2019
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical TrialPierre-Francois Laterre, Scott M Berry, Allan Blemings, et al.
Intensive Care Medicine|April 11, 2018
Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)Tobias Welte, R Phillip Dellinger, Henning Ebelt, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
JAMA|February 24, 2016
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)Mervyn Singer, Clifford S Deutschman, Christopher Warren Seymour, et al.
JAMA|May 20, 2019
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for SepsisChristopher W Seymour, Jason N Kennedy, Shu Wang, et al.
JAMA|May 20, 2019
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical TrialJean-Louis Vincent, Bruno Francois, Igor Zabolotskikh, et al.
Critical Care Medicine|January 29, 2013
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012R Phillip Dellinger, Mitchell M Levy, Andrew Rhodes, et al.
Intensive Care Medicine|January 31, 2013
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012R P Dellinger, Mitchell M Levy, Andrew Rhodes, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
JAMA|October 3, 2019
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical TrialPierre-Francois Laterre, Scott M Berry, Allan Blemings, et al.
Intensive Care Medicine|April 11, 2018
Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)Tobias Welte, R Phillip Dellinger, Henning Ebelt, et al.
Pageof 17